Pfizer (PFE) is expected to report Q2 earnings before the market open on Tuesday, July 31 with a conference call scheduled for 10:00 am ET.
Analysts are looking for EPS of 54c on revenue of $14.9B. The consensus range is 52c-56c for EPS, and $14.66B-$15.38B for revenue, according to First Call. Positive catalysts for the drug company may be seen coming from sales of Celebrex, Enbrel and Lyrica, with investors also optimistic for continued success in Prevnar 13. On the flip side, declining sales in Lipitor, which the company lost exclusivity for in November 2011, will most likely hurt the drug giants revenue number as it did in Q1.